SCHWARZ PHARMA gets off to a good start

Three Months Report 2008

(PresseBox) ( Monheim, )
SCHWARZ PHARMA group sales increased year-on-year in the first quarter of 2008 1. Neupro® (rotigotine) was the top performer. It was followed by Prostavasin® (alprostadil), including Edex® (alprostadil), and Atmadisc® (fluticasone/salmeterol) as additional key sales drivers. Both products recorded yearon- year sales growth. The growth in sales of Neupro® and Prostavasin® (including Edex®) is attributable to the fact that the figures include sales from dealings with companies which have ceased to belong to the scope of consolidation. Overall the sales trend in the first quarter of 2008 was in keeping with the expectations.

The operating result of the SCHWARZ PHARMA group in the first quarter, compared to the prior year period, showed a satisfactory trend.

The group's financial result improved considerably year-on-year. Within the scope of integration into the UCB group, SCHWARZ PHARMA granted an interestbearing vendor loan, generating interest income in the first quarter which was distinctly higher than that recorded in the previous year.

The net result was hence better than in the same quarter of the prior year.

For 2008, SCHWARZ PHARMA plans to make additional investments at the production sites in Shannon/Ireland (fine chemicals) and Zwickau/Germany (bulk manufacture). These projects are progressing as planned.

SCHWARZ PHARMA is maintaining its sales estimate of around €400 million for full fiscal year 2008. The impact of the inability to deliver Neupro® in the USA, announced in March 2008, and the effect of possible measures to restore the ability to deliver are not foreseeable at present. SCHWARZ PHARMA will in all likelihood have a better insight into the situation at the time when its half-year financial report is published. Due to the start-up expenses for producing the drug fesoterodine, SCHWARZ PHARMA continues to expect a negative net result for 2008.

1 As part of the process of integrating SCHWARZ PHARMA AG into the UCB group, 13 affiliated companies ceased to belong to the company's scope of consolidation as per end of fiscal year 2007. All details on the prior year period only relate to continuing operations.

This outlook does not include earnings from the divestment of products or partnerships.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an